bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti‐angiogenic agent apatinib combination therapy.

In total patients, low bTMB (bTMB-L, optimal cutoff = 4) showed significantly longer OS ( I p i = .019) compared with high bTMB (bTMB-H) (Figure 1A and B), and bTMB was significantly associated with disease control rate (DCR) (Figure 1C and D), but not objective response rate (ORR) (Supplementary Figure S4A). Patients with bMSAF-H and bTMB-H (n = 11) are indicated in red, patients with bMSAF-L and bTMB-H (n = 21) are indicated in blue, and those with bMSAF-L and bTMB-L (n = 10) are indicated in green. BMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti-angiogenic agent apatinib combination therapy. [Extracted from the article]